Related Experiment Video
Updated: Jun 19, 2025
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Clinical trial designs of emerging therapies for diabetic kidney disease (DKD)
Ajay K Singh1, Youssef M K Farag2, Zihe Zheng3
1Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Abstract:
Current evidence for medical therapies for diabetic kidney disease (DKD) is largely based on large-scale clinical trials. These trials, however, often exhibit heterogeneity in participant characteristics and baseline kidney function. These differences may lead to misinterpretation in clinical practice, such that treatment effects from different trials are directly compared and generalized to broader populations beyond the population in which each trial was conducted. This is particularly relevant if comparisons on efficacy and safety are made when the underlying study populations are distinctly different. Indeed, key clinical trials evaluating sodium-glucose transport protein-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonist (nsMRA), and glucagon-like peptide-1 receptor agonist (GLP-1RA) differed in recruitment requirements (inclusion/exclusion criteria), resulting in differences in the severity of the underlying kidney disease as well as risk factor profiles. Moreover, these trials defined their primary and secondary outcomes differently. Collectively, these factors lead to distinct study populations with different baseline risks for DKD progression in the placebo arm in each clinical trial. Consequently, a direct head-to-head comparison of the treatment effect between treatments using relative risk measures from placebo-controlled clinical trials alone is not recommended. In addition, healthcare professionals should be equipped to understand the specific target population of clinical trials to avoid over-generalization when drawing conclusions from these trials.
Insights
Directly comparing medical therapies for diabetic kidney disease (DKD) across trials is not recommended due to population differences. Understanding trial specifics is crucial for accurate clinical application of evidence for DKD treatments.
Area of Science:
- Nephrology
- Endocrinology
- Clinical Pharmacology
Background:
- Current evidence for diabetic kidney disease (DKD) therapies relies on large clinical trials.
- These trials often show heterogeneity in patient characteristics and kidney function.
- This heterogeneity can lead to misinterpretation and over-generalization of treatment effects.
Purpose of the Study:
- To highlight the challenges in directly comparing efficacy and safety of DKD therapies across different clinical trials.
- To emphasize the importance of considering trial-specific populations and methodologies.
- To caution against direct head-to-head comparisons of relative risk measures from distinct trials.
Main Methods:
- Analysis of key clinical trials for sodium-glucose transport protein-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (nsMRA), and glucagon-like peptide-1 receptor agonists (GLP-1RA).
- Examination of trial recruitment criteria (inclusion/exclusion), leading to variations in disease severity and risk factor profiles.
- Review of differing primary and secondary outcome definitions across trials.
Main Results:
- Significant differences observed in study populations across major DKD therapy trials.
- Variations in baseline disease severity and risk factors were noted due to differing inclusion/exclusion criteria.
- Inconsistent outcome definitions contribute to distinct baseline risks in placebo arms.
Conclusions:
- Direct head-to-head comparison of treatment effects using relative risk from placebo-controlled trials alone is not advisable.
- Healthcare professionals must understand the specific target populations of clinical trials.
- Avoid over-generalization of findings; interpret trial results within their specific contexts for diabetic kidney disease management.
